Two complementary studies show that defibrotide can successfully suppress the formation and progression of neutrophil extracellular traps, or NETs, which are web-like networks of toxic proteins that play a role in forming blood clots and promoting inflammation in several disease, including COVID-19. Researchers say findings may set the stage for defibrotide clinical trials in potentially several diseases.
